Moderna, Battered Since the COVID Vaccine Era, Stages a Stunning Comeback With a Personalized mRNA Cancer Vaccine
🎧 Post Summary
Moderna and Merck announced that their jointly developed personalized mRNA cancer vaccine, intismeran autogene, met its main goals in a Phase 3 melanoma trial — sending Moderna’s stock soaring as much as 177% in a single day. The vaccine is custom-made by analyzing the unique mutations found in each patient’s own tumor, and is given together with Merck’s immunotherapy drug Keytruda to suppress cancer recurrence and spread. In an earlier Phase 2 trial, the combination cut the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59%. The companies are aiming to file for regulatory approval within months, with patients potentially benefiting as early as next year. That said, detailed data haven’t been presented at a medical conference yet, and the news arrives at a time when the U.S. government has been cutting funding tied to mRNA vaccines. In Korea, biotech stocks like Samsung Biologics rallied in premarket trading, and domestic companies working on similar technology are getting a fresh look too.
On the 19th (local time), Moderna’s name once again swept across headlines worldwide — this time not for COVID-19, but for a cancer vaccine. Right after the announcement, Moderna’s stock jumped nearly 50% in premarket trading alone, then surged as much as 177% intraday during regular trading, marking its best single-day gain on record. So what exactly happened? Let’s break it down in plain terms.
① What Happened — The Phase 3 Announcement and the Stock Surge
On the 19th, Moderna and U.S. drugmaker Merck announced that their jointly developed personalized mRNA cancer vaccine, intismeran autogene (code name V940), met both its primary and secondary endpoints in the Phase 3 INTerpath-001 trial. The trial enrolled more than 1,100 patients with stage 2B–4 melanoma (a type of skin cancer) who had undergone complete surgical removal of their tumors. The group receiving intismeran together with Merck’s immunotherapy drug Keytruda showed statistically significant improvement over the Keytruda-alone group in both recurrence-free survival and distant-metastasis-free survival.
On the news, Moderna’s stock jumped nearly 50% in premarket trading on the 19th ahead of the U.S. market open, then surged as much as 176.97% intraday during regular trading — the best single-day performance in Moderna’s history as a public company. Merck’s shares, developed alongside Moderna, also rose about 6–8%.
② How Exactly Does This Vaccine Work?
The name sounds complicated, but the principle is fairly simple. Every cancer cell carries unique mutations not found in normal cells, and the abnormal protein fragments those mutations produce are called “neoantigens.” Intismeran analyzes a patient’s own tumor tissue to identify up to 34 neoantigens unique to that patient, then custom-builds an mRNA vaccine encoding them for that individual. Once injected, the vaccine trains the immune system to recognize those neoantigens as “the enemy” — and pairing it with Merck’s Keytruda (an immune checkpoint inhibitor) helps immune cells attack the cancer cells more aggressively.
Here’s a simple way to think about it: if the COVID-19 vaccine told immune cells in advance what the virus’s spike protein looked like, this cancer vaccine tells each individual patient’s immune system, “here’s exactly what your specific cancer cells look like.” If the COVID vaccine was “off-the-rack,” this cancer vaccine is closer to a suit tailored fresh for every patient.
③ Just How Meaningful Is This Result?
This Phase 3 result is drawing attention because it’s the first time a personalized mRNA cancer therapy has produced a positive result in a late-stage (Phase 3) trial. In the earlier Phase 2 trial, the same combination therapy reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared with Keytruda alone — and this Phase 3 trial reconfirmed a similar pattern of improvement.
That said, there are caveats worth noting. What was announced is interim Phase 3 data; the detailed figures haven’t been released yet and are expected to be presented at an upcoming international medical conference. Overall survival data — whether the treatment actually extends how long patients live — is still being tracked as the trial continues. In short: the signal that this works is clear, but the fine print and final confirmation will take a bit more time.
④ Why Did the Stock Jump This Much?
Moderna grew rapidly on COVID-19 vaccine sales during the pandemic, but its stock had been under heavy pressure since as demand for COVID shots declined. This result is being read as proof that Moderna has a genuine new growth engine beyond its “COVID vaccine company” label. Industry analysts have said the melanoma indication alone could generate billions of dollars in sales, and the combination therapy is already in trials for additional indications beyond melanoma, including lung, kidney, bladder, pancreatic, and stomach cancers. According to YTN, Moderna is now seen as having a foothold in the oncology market, estimated at roughly $240 billion.
The stock surge also benefited the company’s founders. Co-founder Robert Langer’s net worth reportedly jumped from about $730 million to $1.7 billion in a single day; fellow co-founder Noubar Afeyan’s net worth rose by about $184 million to $2.1 billion; and CEO Stéphane Bancel’s fortune grew by $2.5 billion to $4.8 billion. Bancel called the results “as big a day for humanity as Nov. 16, 2020,” referring to the day Moderna announced its COVID-19 vaccine’s successful clinical results.
⑤ The Backdrop — America’s Ongoing Fight Over mRNA
It’s worth knowing that this good news arrives against a backdrop of the U.S. government scaling back support for mRNA technology. Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly voiced skepticism about mRNA vaccines. Last May, Moderna’s roughly $766 million contract to develop a pandemic influenza (bird flu) mRNA vaccine was canceled. Then last August, the Biomedical Advanced Research and Development Authority (BARDA) announced it was terminating 22 mRNA-related contracts with Moderna, Pfizer, and others, worth about $500 million combined. At the time, Kennedy argued there was “data showing these vaccines fail to protect effectively” against upper respiratory infections — a claim that numerous health experts, including Dr. Paul Offit, pushed back on, maintaining that mRNA vaccines are “remarkably safe.”
Against that backdrop, this cancer vaccine’s clinical success is being read as a signal that — separate from the political debate over infectious-disease vaccines — mRNA technology itself is delivering clear results in the new arena of cancer treatment.
⑥ What Impact Did This Have on Korea’s Stock Market?
The tailwind from Moderna reached Korean markets too. In premarket trading on the Next Trade platform on the 20th, Samsung Biologics rose about 5% from the previous close, reflecting improved sentiment toward Korean biotech stocks on hopes for commercializing mRNA-based cancer therapies. Neogenlogic, a subsidiary of SCL Science developing an AI-based personalized cancer vaccine domestically, also drew renewed attention given its similar technology direction.
Things Worth Keeping in Mind
- What was released is interim Phase 3 data. Detailed figures and overall survival data still need to be confirmed through future international conference presentations.
- A successful trial doesn’t automatically translate into regulatory approval or actual prescriptions. Moderna and Merck are aiming to file for approval within months, but the review and approval process itself will take additional time.
- A stock surge tied to a single clinical announcement is, by nature, a highly volatile event. Investment decisions on related stocks deserve a cautious approach that also weighs the release of detailed data and the progress of regulatory review.
- This article summarizes recently reported clinical trial results and does not recommend any specific treatment or provide medical advice. Please consult your own physician regarding any personal health matters.
To sum up, this is a case of Moderna — a name made famous by its COVID-19 vaccine — extending mRNA technology into the new territory of cancer treatment and producing a meaningful clinical result. Detailed data disclosure and regulatory approval remain as next steps, but the possibility this opens up for personalized mRNA cancer therapy means both the medical and investment communities are likely to keep a close eye on this story for some time.
References
- CNN – “Moderna and Merck say melanoma vaccine succeeded in large trial” (cnn.com)
- Forbes – “Moderna Shares Skyrocket 125% Toward Best Day Ever—On Success Of Cancer Drug Trial” (forbes.com)
- Hankyung (Korea Economic Daily) – “Merck, Moderna post positive Phase 3 cancer vaccine results; Moderna shares jump 88%” (hankyung.com)
- Seoul Economic Daily – “Moderna surges 177% in a day… Samsung Biologics up 5% in premarket” (sedaily.com)
- Seoul Shinmun – “Moderna, Merck cancer vaccine succeeds in Phase 3… SCL Science subsidiary Neogenlogic’s ‘AI cancer vaccine’ back in spotlight” (seoul.co.kr)
- Medical Newspaper (bosa.co.kr) – “Moderna cancer vaccine Phase 3 success, stock surges” (bosa.co.kr)
- Healthcare Dive – “HHS abandons mRNA vaccine research” (healthcaredive.com)